Privacy Policy | Cookie Policy | LinkedIn
0%
About Oranda

About Oranda

An experienced team with a mission to make a big difference in rare diseases.

Our Mission

MedicineAccess

01

We're building a rare disease company that is deliberate and purposeful in its approach

02

We are agile and identify new opportunities to broaden patient access to new and existing medicines

03

We move quickly and cost-effectively to rapidly commercialise products

04

We are curious and energetic with a problem-solving mindset

05

We use new ways of working whenever we can to create value and support scale-up

The Oranda Team

Our Team

An experienced, entrepreneurial team united by a shared mission to make a measurable difference in rare diseases. Meet the board:

Ahmed Al-Derzi

Ahmed Al-Derzi

CEO & Co-Founder

Ahmed has over 30 years of experience as an entrepreneur and business leader in generic and speciality medicines.

John Irwin

John Irwin

Chief Commercial Officer & Co-Founder

John has more that 25 years of experience in value creation across orphan medicines and rare disease.

Dr Kieran Rooney

Dr Kieran Rooney

Non-Executive Director

Kieran brings over 30 years of experience in corporate and business development across biopharma, with expertise in rare disease.

Our Values

Values that shape how we work

Compassion, Respect & Humility
01

Compassion, Respect & Humility

We put patients and people first, listening carefully, acting with empathy, and recognising that meaningful impact starts with respect.

Openness & Diversity of Thought
02

Openness & Diversity of Thought

We value different perspectives and experiences, knowing that better decisions come from open dialogue and inclusive thinking.

Innovation & Challenge
03

Innovation & Challenge

We challenge convention and apply fresh thinking to solve complex problems, always focused on creating practical impact.

Collaboration & Meaningful Work
04

Collaboration & Meaningful Work

We work together with purpose, supporting one another to deliver work that matters for patients, healthcare systems and commercial partners.

OTD-NP-GBR-00002 | March 2026